Omeros Corp (OMER)

$3.86 -0.16 (-3.98%)
Market Cap 228.83M
Revenue (ttm) 0.00
Net Income (ttm) -156.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.74
Volume 905,200
Avg Vol 1,134,126
Day's Range N/A - N/A
Shares Out 61.76M
Stochastic %K 54%
Beta 2.26
Analysts Sell
Price Target $22.50

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
Newtimmy
Newtimmy Aug. 7 at 1:23 AM
$OMER Earnings
0 · Reply
Vanhalen33
Vanhalen33 Aug. 7 at 12:19 AM
$OMER What’s up with this sentiment score of 29?
2 · Reply
SteadyasSheGoes
SteadyasSheGoes Aug. 6 at 4:48 PM
$OMER there's that unusual trading again....
0 · Reply
Stocksfirst
Stocksfirst Aug. 6 at 2:39 PM
$OMER - just can’t hold $4…..does that tell us anything??
3 · Reply
betonthenews
betonthenews Aug. 6 at 1:27 PM
$OMER My speculation only: the partnership may be for Narsoplimab and Zaltenibart rest of world market, OMER keeps US market. It makes sense for OMER to partner them out to a big pharm, too costly and time consuming for OMER to undertake those efforts, IMO.
1 · Reply
ThreeGirls
ThreeGirls Aug. 6 at 1:10 PM
$OMER someone said that OMER should issue a PR with a LOI on the potential deal. I forget who so I apologize. I responded that they would never do that and that companies don’t do that. Whoever I was discussing it with said that companies do PR LOIs. Well first there would need to an LOI in place to PR. And secondly it’s is rare, a big exception that companies do. LOIs are usually kept private unless they reach a stage where the company has a legal or strategic reason to disclose — and that’s uncommon. And PRing an LOI to raise the SP is not a reason. LOIs are non-binding and subject to change or cancellation. The SEC expects material information to be complete. And if it’s not strategic, it would be seen for what it is, manipulation. It would raise serious regulatory and reputational concerns, especially if the deal never materializes. I don’t see it happening
2 · Reply
naturegirl669
naturegirl669 Aug. 6 at 7:49 AM
$OMER - Thanks hoffspeed for the clarification below: "If it means anything, my wife is VP at a pharma company. She said FDA is delaying due do staffing issues, her company also has delays."
1 · Reply
naturegirl669
naturegirl669 Aug. 6 at 3:56 AM
$OMER - TODAY'S ACTION?.....T"rump says pharma tariffs could go to 250%, threatens EU if it fails on investment pledge." "We'll be putting a initially small tariff on pharmaceuticals, but in one year — one and a half years, maximum — it's going to go to 150%. And then it’s going to go to 250%, because we want pharmaceuticals made in our country," Trump said during a CNBC interview. Trump also threatened the European Union with increased tariffs if it failed to live up to a pledge to invest some $600 billion in the US.
0 · Reply
Willie95
Willie95 Aug. 6 at 12:07 AM
$OMER ....Perhaps this recent event may benefit Omeros down the road..... "HHS Sec­re­tary Robert F. Kennedy Jr. an­nounced the can­ce­la­tion or re­work­ing of al­most two dozen con­tracts for the de­vel­op­ment of mR­NA vac­cines, in­clud­ing for flu and Covid-19, on Tues­day night..."...
0 · Reply
albert88
albert88 Aug. 5 at 7:56 PM
$OMER Just buy and wait.
1 · Reply
Latest News on OMER
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jul 25, 2025, 8:00 AM EDT - 12 days ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 27, 2025, 8:30 AM EDT - 5 weeks ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 24, 2025, 8:30 AM EDT - 6 weeks ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Jun 10, 2025, 12:53 PM EDT - 2 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 27, 2025, 11:12 PM EDT - 2 months ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

May 27, 2025, 7:20 AM EDT - 2 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter

AGL ANIP

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 2 months ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

Omeros Corporation Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 2 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 5:05 PM EDT - 3 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 12, 2025, 10:35 AM EDT - 3 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

May 6, 2025, 9:16 AM EDT - 3 months ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 4 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 10, 2025, 9:10 AM EDT - 4 months ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Apr 8, 2025, 9:00 AM EDT - 4 months ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:57 PM EDT - 4 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 31, 2025, 4:02 PM EDT - 4 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 28, 2025, 7:39 AM EDT - 4 months ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 26, 2025, 9:15 AM EDT - 4 months ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Mar 21, 2025, 9:15 AM EDT - 4 months ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 24, 2025, 4:44 PM EST - 5 months ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 20, 2025, 9:10 AM EST - 5 months ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 14, 2025, 9:00 AM EST - 6 months ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Feb 10, 2025, 9:00 AM EST - 6 months ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Jan 16, 2025, 9:15 AM EST - 7 months ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 12:28 PM EST - 8 months ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 19, 2024, 9:15 AM EST - 8 months ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 10, 2024, 8:45 AM EST - 8 months ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Dec 2, 2024, 8:45 AM EST - 8 months ago

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Nov 21, 2024, 9:15 AM EST - 9 months ago

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:22 PM EST - 9 months ago

Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript

Omeros Corporation Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:02 PM EST - 9 months ago

Omeros Corporation Reports Third Quarter 2024 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Nov 11, 2024, 4:11 PM EST - 9 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Oct 24, 2024, 8:45 AM EDT - 10 months ago

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:05 AM EDT - 1 year ago

Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript

Omeros Corporation Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2024 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Aug 5, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:23 PM EDT - 1 year ago

Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript

Omeros Corporation Reports First Quarter 2024 Financial Results

May 15, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2024 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

May 10, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

May 9, 2024, 8:50 AM EDT - 1 year ago

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Apr 1, 2024, 8:09 PM EDT - 1 year ago

Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Apr 1, 2024, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Feb 20, 2024, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Feb 1, 2024, 9:11 AM EST - 1 year ago

Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust

Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Nov 27, 2023, 1:18 AM EST - 1 year ago

Omeros: Why It Is Worthwhile To Bet On Narsoplimab

Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript

Nov 10, 2023, 10:32 AM EST - 1 year ago

Omeros Corporation (OMER) Q3 2023 Earnings Call Transcript

Omeros Corporation Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:02 PM EST - 1 year ago

Omeros Corporation Reports Third Quarter 2023 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

Nov 6, 2023, 8:00 AM EST - 1 year ago

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023

Newtimmy
Newtimmy Aug. 7 at 1:23 AM
$OMER Earnings
0 · Reply
Vanhalen33
Vanhalen33 Aug. 7 at 12:19 AM
$OMER What’s up with this sentiment score of 29?
2 · Reply
SteadyasSheGoes
SteadyasSheGoes Aug. 6 at 4:48 PM
$OMER there's that unusual trading again....
0 · Reply
Stocksfirst
Stocksfirst Aug. 6 at 2:39 PM
$OMER - just can’t hold $4…..does that tell us anything??
3 · Reply
betonthenews
betonthenews Aug. 6 at 1:27 PM
$OMER My speculation only: the partnership may be for Narsoplimab and Zaltenibart rest of world market, OMER keeps US market. It makes sense for OMER to partner them out to a big pharm, too costly and time consuming for OMER to undertake those efforts, IMO.
1 · Reply
ThreeGirls
ThreeGirls Aug. 6 at 1:10 PM
$OMER someone said that OMER should issue a PR with a LOI on the potential deal. I forget who so I apologize. I responded that they would never do that and that companies don’t do that. Whoever I was discussing it with said that companies do PR LOIs. Well first there would need to an LOI in place to PR. And secondly it’s is rare, a big exception that companies do. LOIs are usually kept private unless they reach a stage where the company has a legal or strategic reason to disclose — and that’s uncommon. And PRing an LOI to raise the SP is not a reason. LOIs are non-binding and subject to change or cancellation. The SEC expects material information to be complete. And if it’s not strategic, it would be seen for what it is, manipulation. It would raise serious regulatory and reputational concerns, especially if the deal never materializes. I don’t see it happening
2 · Reply
naturegirl669
naturegirl669 Aug. 6 at 7:49 AM
$OMER - Thanks hoffspeed for the clarification below: "If it means anything, my wife is VP at a pharma company. She said FDA is delaying due do staffing issues, her company also has delays."
1 · Reply
naturegirl669
naturegirl669 Aug. 6 at 3:56 AM
$OMER - TODAY'S ACTION?.....T"rump says pharma tariffs could go to 250%, threatens EU if it fails on investment pledge." "We'll be putting a initially small tariff on pharmaceuticals, but in one year — one and a half years, maximum — it's going to go to 150%. And then it’s going to go to 250%, because we want pharmaceuticals made in our country," Trump said during a CNBC interview. Trump also threatened the European Union with increased tariffs if it failed to live up to a pledge to invest some $600 billion in the US.
0 · Reply
Willie95
Willie95 Aug. 6 at 12:07 AM
$OMER ....Perhaps this recent event may benefit Omeros down the road..... "HHS Sec­re­tary Robert F. Kennedy Jr. an­nounced the can­ce­la­tion or re­work­ing of al­most two dozen con­tracts for the de­vel­op­ment of mR­NA vac­cines, in­clud­ing for flu and Covid-19, on Tues­day night..."...
0 · Reply
albert88
albert88 Aug. 5 at 7:56 PM
$OMER Just buy and wait.
1 · Reply
betonthenews
betonthenews Aug. 5 at 6:45 PM
$OMER So far, very interesting action today.....
1 · Reply
betonthenews
betonthenews Aug. 5 at 4:40 PM
$OMER @seanleecfa GD has wasted all his previous anti-dilution efforts now with 67.126m, 15.6% dilution, if signed partnership in OCT, he may get the upfront cash at earliest by end of Nov, then he needs 3 months cash of $30+M dilution again to keep about $25M at all time due to the loan. GD is not in place to maximize value of the partnership now, he has to do a math on what is the best of partnership early possible Vs pressure of more dilution, IMO.
2 · Reply
betonthenews
betonthenews Aug. 5 at 3:00 PM
$OMER ALXN updates P3 adult TMA primary endpoint finish date again from June 30 to July 31 today, ALXN 100% is trying to delay the topline data out once more, it is sure indication of weak data and may be AZN is the partner GD is talking to, good sign the partnership may be "SOON", GD better be more transparent about the partnership progress on earnings CC next week, IMO. https://clinicaltrials.gov/study/NCT04543591?tab=history&a=28&b=29#version-content-panel
1 · Reply
MayorofMNKD
MayorofMNKD Aug. 4 at 5:09 PM
$OMER ….as of 4 days ago there is no partner deal to announce…IMO if and when he gets a deal done (in principal) it will be PR’d as an LOI within 4 business days. This is the fastest way to get the deal out in the open and provide potential upward momentum and strength to the share price prior to an actual completed deal. Until then we’re all speculating. What gives me a lot of hope that we are close to this event and hopefully not predicated on approval is the fact someone gave us 22 million for stock at a premium, No one gives money like this as a band-aid without seeing light at the end of the tunnel. … and what that means IMO is that someone is doing the deal regardless of NARSO approval.
3 · Reply
UltimoDaBaggie
UltimoDaBaggie Aug. 4 at 4:15 PM
$OMER @ThreeGirls What do you think the risk of bankruptcy is in OMER’s case? 1/10 ?
7 · Reply
betonthenews
betonthenews Aug. 4 at 3:32 PM
$OMER My speculation is that the partnership deal and BLA's chances of approval are related. If the partnership is signed by mid of Sept, it means the partner see NARSO approval and has gotten as much as GD is willing to give with the short-term financing pressure, IMO.
1 · Reply
SteadyasSheGoes
SteadyasSheGoes Aug. 4 at 2:25 PM
$OMER Now that partnership details have been disclosed, does that require Greg to also disclose if the partnership terms have been withdrawn or the terms significantly changed?
5 · Reply
MinnieSteve3
MinnieSteve3 Aug. 4 at 1:14 PM
$OMER I'm guessing Omeros will announce earnings and have the earnings call on Thursday August 14 after hours. I can't see then waiting until August 15 and announcing earnings and having the earnings call after hours on a Friday afternoon.
2 · Reply
SteadyasSheGoes
SteadyasSheGoes Aug. 3 at 4:30 PM
$OMER Shuttering all operations to focus on Narso approval made sense with a Sept PDUFA date. Now, with the 90 day delay it will be even longer until our "most promising" drug candidate, Zaltenibart resumes trials. Greg really has bet it all on Narso approval and/or a partnership. Hope we are given useful clarity at the upcoming 2q EC.
4 · Reply
Stocksfirst
Stocksfirst Aug. 2 at 10:55 PM
$OMER - where is Mike Logan these days? He was willing to wait until March of this year before getting “impatient”….😂
1 · Reply
TarponTime
TarponTime Aug. 2 at 12:16 PM
$OMER In the last week I have heard every possible scenario explained. From complete collapse …to Alexion buyout.. To CRL Of Narso with a chance of a miracle… Clearly us Long holding Longs are sitting with our backs to the wall. At this point no one knows. Especially Me !!!
2 · Reply
MinnieSteve3
MinnieSteve3 Aug. 1 at 11:45 PM
$OMER This was a bad day to stop tracking with XBI. XBI was up today.
1 · Reply